Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

AbundRX vs VyrarX

AbundRX
Graded #181

Lower grade

vs+2
VyrarX
Graded #145

Higher grade

The verdict

VyrarX takes it — 68.6/100 to 66.6/100, but only just.

VyrarX grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. VyrarX is a LegitScript-certified telehealth platform offering compounded semaglutide (from $179/month) and compounded tirzepatide (from $329/month) via weekly injection, prescribed by licensed US physicians. AbundRX is close behind and may still be the better fit — see the factor split below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueAbundRX +6
67
61
Dose & formulationEven
64
64
Clinical oversightVyrarX +5
79
84
Labs & monitoringVyrarX +19
53
72
FulfillmentAbundRX +3
74
71
Contract termsEven
55
55
AbundRX · left barVyrarX · right bar

The numbers

MetricAbundRXVyrarX
WeighScore66.6/10068.6/100
GradeCC
Scorecard rank#181#145
Semaglutide$179/mo (compounded)$179/mo (starting dose, compounded)
Tirzepatide$279/mo (compounded)$329/mo (starting dose, compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
AbundRX

Graded #181 · C

Strengths

  • Two clear compounded GLP-1 pathways with transparent pricing — semaglutide $179/mo and tirzepatide $279/mo
  • Fast, free shipping and a simple few-minute online health assessment
  • Provider-guided care connecting patients with licensed US clinicians
  • Publishes Terms, Privacy, and Refund policies

Where it loses points

  • Claims LegitScript certification in text but displays no verifiable seal or listing
  • Compounded medications are not FDA-approved (the site discloses this) — not brand Wegovy, Ozempic, Zepbound, or Mounjaro
  • Compounding pharmacy not named; no HIPAA notice found; state availability not published
  • Heavily hedged marketing language ('may include', 'helping connect patients') — reads like a lead-generation platform
VyrarX

Graded #145 · C

Strengths

  • LegitScript certified with active seal (ID 51177727)
  • Semaglutide starting at $179/month with free shipping included
  • 1:1 direct provider messaging and personalized titration plan in every plan
  • Nutrition coaching included with the weight-loss program
  • Provider review completed within 24 hours; no insurance required

Where it loses points

  • Tirzepatide at $329/month starting is at the high end of the compounded market
  • Compounding pharmacy not named on any public page
  • No physician names or clinical leadership disclosed publicly
  • Only 47 states covered — the 3 excluded states are not named on the site
  • Labs not included in the weight-loss plan

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard